Trials / Completed
CompletedNCT03027284
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
A Phase I Study of Merestinib Monotherapy or in Combination With Other Anti-Cancer Agents in Japanese Patients With Advanced and/or Metastatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.
Conditions
- Advanced Cancer
- Metastatic Cancer
- Biliary Tract Carcinoma
- Cholangiocarcinoma
- Gall Bladder Carcinoma
- Solid Tumor
- Non-Hodgkin's Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Merestinib | Administered orally |
| DRUG | Cisplatin | Administered IV |
| DRUG | Gemcitabine | Administered IV |
Timeline
- Start date
- 2017-02-03
- Primary completion
- 2019-06-20
- Completion
- 2020-03-17
- First posted
- 2017-01-23
- Last updated
- 2020-05-19
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03027284. Inclusion in this directory is not an endorsement.